As expected, according to the study design, no significant differences were found for age at inclusion or gender between all groups in the discovery cohort (50% male, p = 1.000; age control: 69.5 ± 8.08; and age iPD: 71.6 ± 9.17, p = 0.4469) or in the validation cohort (46.6% male, p = 0.499; age control: 65.3 ± 8.3; age iPD: 69.2 ± 11.3; and age LRRK2-PD 70.0 ± 9.0, p = 0.271). Here, LRRK2 is linked to Parkinson disease.